Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Constance CareWAR:CCR 20 3-Year EBITDA Growth Rate is -60.70% as of Jun. 2026. GuruFocus rates WAR:CCR with a GF Score™ of 20/100 and a GF Value™ of zł0.15 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 523 Healthcare Providers & Services companies, Constance Care ranks worse than 97.9% on this metric.
During the past 12 months, Constance Care's average EBITDA Per Share Growth Rate was -96.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -60.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Constance Care was -54.80% per year. The lowest was -60.70% per year. And the median was -57.75% per year.
Constance Care (WAR:CCR) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Constance Care 3-Year EBITDA Growth Rate Related Terms
WAR:CCR vs HCA, THC, EHC: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Constance Care's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Constance Care 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Constance Care's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Constance Care's 3-Year EBITDA Growth Rate falls into.
Constance Care 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -60.70% mean?
Constance Care (WAR:CCR) has a 3-Year EBITDA Growth Rate of -60.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Constance Care and its competitors. According to the industry distribution chart, Constance Care ranks #512 out of 523 companies in the Healthcare Providers & Services industry, placing it in the top 97.9%.
Is Constance Care's 3-Year EBITDA Growth Rate too high?
Constance Care's current 3-Year EBITDA Growth Rate is -60.70%. Based on the distribution chart, Constance Care ranks #512 out of 523 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Constance Care has a GF Score™ of 20/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Constance Care's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Constance Care ranks #512 out of 523 companies for 3-Year EBITDA Growth Rate. This places Constance Care in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 9.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 9.90, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Constance Care and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Constance Care's current 3-Year EBITDA Growth Rate is -60.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Constance Care stock overvalued right now?
Based on GuruFocus' analysis, Constance Care (WAR:CCR) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.15, compared to a current price of zł8.50 — trading 5566.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is -60.70%. Constance Care's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Constance Care (WAR:CCR), the current 3-Year EBITDA Growth Rate is -60.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Constance Care (WAR:CCR) Overvalued in 2026?
Based on GuruFocus' analysis, Constance Care stock appears to be overvalued.
The current stock price of zł8.50 is trading 5566.7% above its estimated GF Value™ of zł0.15.
GuruFocus considers Constance Care to be Significantly Overvalued.
Key valuation signals for WAR:CCR:
3-Year EBITDA Growth Rate: -60.70%
GF Value™: zł0.15 vs. price of zł8.50 (5566.7% above fair value)
No single metric tells the full story. See the WAR:CCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Constance Care SA conducts physiotherapeutic activities aimed at improving the quality of health and life of people suffering both from musculoskeletal disorders as a result of various random events, diseases or related to the aging of the body, as well as the rehabilitation of cognitive functions in children and adults.
20GF Score
Get the complete analysis for WAR:CCR
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:CCR has been successfully added to your 
